| Literature DB >> 30532517 |
Masashi Sakamoto1, Ryuya Hashimoto1, Izumi Yoshida1, Makoto Ubuka1, Takatoshi Maeno1.
Abstract
PURPOSE: To investigate the potential risk factors for neovascular glaucoma (NVG) after vitrectomy in eyes with proliferative diabetic retinopathy. SUBJECTS AND METHODS: In this retrospective, observational, comparative study, patients with proliferative diabetic retinopathy who underwent vitrectomy at Toho University Sakura Medical Center between December 2011 and November 2016 and who were followed for ≥12 months after surgery were included. Subject parameters examined included age, glycated hemoglobin (HbA1c), fasting blood glucose, administration of insulin, and estimated glomerular filtration rate. Ocular parameters examined included preoperative best-corrected visual acuity, preoperative IOP, operative history (specifically panretinal photocoagulation), lens status, ocular pathology (eg, iris/angle neovascularization, tractional retinal detachment, diabetic macular edema, vitreous hemorrhage, combined tractional retinal detachment), intraoperative retinal tamponade use, vitrectomy gauge, combined lens extraction/vitrectomy procedure, subsequent surgical procedures, and pre- and postoperative intravitreal bevacizumab. Correlations between variables and postoperative NVG development were examined using logistic regression analyses (backward elimination method).Entities:
Keywords: neovascular glaucoma; proliferative diabetic retinopathy; vitrectomy
Year: 2018 PMID: 30532517 PMCID: PMC6241680 DOI: 10.2147/OPTH.S184959
Source DB: PubMed Journal: Clin Ophthalmol ISSN: 1177-5467
Subject and ocular characteristics in patients who had undergone vitrectomy to treat proliferative diabetic retinopathy
| Characteristics | Without NVG (n=194) | With NVG (n=60) | |
|---|---|---|---|
| Male (%) | 140 (72.2) | 48 (80.0) | 0.378 |
| Age (years) | 54.8±10.8 (27–83) | 52.7±8.8 (26–66) | 0.152 |
| History of PRP (%) | 134 (69.1) | 41 (68.3) | 1.000 |
| Phakic before vitrectomy (%) | 169 (87.1) | 53 (88.3) | 1.000 |
| Iris/angle neovascularization (%) | 5 (2.6) | 7 (11.7) | 0.019 |
| TRD (%) | 40 (20.6) | 22 (36.7) | 0.018 |
| Combined TRD (%) | 11 (5.7) | 2 (3.3) | 0.738 |
| Macular edema (%) | 25 (12.9) | 12 (20.0) | 0.192 |
| Vitreous hemorrhage (%) | 142 (73.2) | 33 (55.0) | 0.019 |
| Lens extraction (%) | 157 (80.9) | 51 (85.0) | 1.000 |
| Pseudophakic after vitrectomy (%) | 182 (93.8) | 58 (96.7) | 1.000 |
| Retinal tamponade use (%) | 82 (42.3) | 34 (56.7) | 0.062 |
| Vitrectomy gauge using a 20G (%) | 42 (21.6) | 11 (18.3) | 0.706 |
| IVB preoperation (%) | 27 (13.9) | 9 (15.0) | 0.829 |
| IVB immediately after vitrectomy (%) | 43 (22.1) | 3 (5.0) | 0.193 |
| Repeat surgery (%) | 18 (9.3) | 7 (11.7) | 0.611 |
| Follow-up period (months) | 23.0±15.0 (12–66) | 7.2±6.2 (1–24) | ,0.001 |
| Preoperative logMAR BCVA | 1.21±0.69 (0.10–2.30) | 1.19±0.62 (0.22–2.80) | 0.994 |
| Preoperative IOP (mmHg) | 13.8±3.3 (7–21) | 15.0±3.2 (8–21) | 0.024 |
| Postoperative logMAR BCVA | 0.52±0.74 (0.10–2.30) | 1.28±0.84 (−0.08 to 2.30) | ,0.001 |
| Postoperative IOP (mmHg) | 14.5±10.3 (7–27) | 34.4±11.0 (22–60) | ,0.001 |
| HbA1c (%) | 7.7±1.7 (4.5–13.8) | 7.2±1.5 (4.8–13.3) | 0.110 |
| Fasting blood sugar (mg/dL) | 174.9±76.1 (48–486) | 178.6±68.0 (73–383) | 0.491 |
| eGFR (mL/min/1.73 m2) | 66.9±29.5 (8–159) | 73.9±27.3 (16–132) | 0.089 |
| Hemodialysis (%) | 3 (1.5) | 0 (0) | 1.000 |
| Administration of insulin (%) | 52 (26.8) | 22 (36.7) | 0.175 |
Notes: Data are presented as mean±SD (range) unless otherwise specified.
Abbreviations: eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; IVB, intravitreal bevacizumab; logMAR BCVA, logarithm of the mean angle of resolution best-corrected visual acuity; NVG, neovascular glaucoma; PRP, panretinal photocoagulation; TRD, tractional retinal detachment.
Logistic regression analyses and the backward elimination method of neovascular glaucoma risk factors in subjects who underwent vitrectomy to treat proliferative diabetic retinopathy
| Logistic regression analyses | Backward elimination method | |||||
|---|---|---|---|---|---|---|
| Partial regression coefficient | OR (95% CI) | Partial regression coefficient | OR (95% CI) | |||
| Male sex | 0.397 | 1.49 (0.71–3.11) | 0.290 | |||
| Age (years) | −0.018 | 0.98 (0.95–1.01) | 0.211 | |||
| History of PRP | −0.031 | 0.97 (0.50–1.86) | 0.925 | |||
| Phakic before vitrectomy | 0.048 | 1.05 (0.42–2.58) | 0.917 | |||
| Iris/angle neovascularization | 1.504 | 4.50 (1.32–15.38) | 0.016 | 1.369 | 3.93 (1.05–14.65) | 0.042 |
| TRD | 0.822 | 2.28 (1.18–4.39) | 0.014 | |||
| Combined TRD | −0.497 | 0.61 (0.13–2.83) | 0.527 | |||
| Macular edema | 0.540 | 1.72 (0.78–3.78) | 0.180 | |||
| Vitreous hemorrhage | −0.770 | 0.46 (0.25–0.87) | 0.016 | |||
| Lens extraction | 0.294 | 1.34 (0.58–3.10) | 0.491 | |||
| Pseudophakic after vitrectomy | −0.396 | 0.67 (0.14–3.17) | 0.617 | |||
| IVB preoperation | 0.062 | 1.06 (0.45–2.51) | 0.888 | |||
| IVB immediately after vitrectomy | 0.979 | 2.66 (0.58–12.28) | 0.210 | |||
| Retinal tamponade use | 0.615 | 1.85 (1.00–3.41) | 0.050 | 0.781 | 2.18 (1.13–4.23) | 0.021 |
| Retinal tamponade use (ordinal scale: none: 0, air: 1, gas: 2, silicone: 3) | 0.245 | 1.28 (0.94–1.74) | 0.119 | |||
| Vitrectomy gauge using a 20G | −0.194 | 0.82 (0.38–1.78) | 0.622 | |||
| Repeat surgery | 0.211 | 1.24 (0.46–3.31) | 0.674 | |||
| Preoperative logMAR BCVA | −0.027 | 0.97 (0.63–1.51) | 0.903 | |||
| Preoperative IOP | 0.112 | 1.12 (1.02–1.23) | 0.022 | 0.155 | 1.17 (1.05–1.30) | 0.005 |
| HbA1c | −0.172 | 0.84 (0.69–1.03) | 0.089 | −0.349 | 0.71 (0.56–0.90) | 0.004 |
| Fasting blood sugar | 0.0006 | 1.00 (1.00–1.00) | 0.751 | |||
| eGFR | 0.008 | 1.01 (1.00–1.02) | 0.127 | |||
| Administration of insulin | 0.463 | 1.59 (0.84–3.01) | 0.157 | 0.737 | 2.09 (1.02–4.30) | 0.045 |
Notes:
Indicates P<0.05.
Retinal tamponade use (ordinal scale: none: 0, air: 1, gas: 2, silicone: 3) was not adopted in the backward elimination method.
Indicates P<0.01.
Abbreviations: eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; IVB, intravitreal bevacizumab; logMAR BCVA, logarithm of the mean angle of resolution best-corrected visual acuity; PRP, panretinal photocoagulation; TRD, tractional retinal detachment.